SCHEMBL19950452

SCHEMBL19950452

COc1cc(NC(=O)O)cnc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 3/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
KCNQ3 O43525 1/20 0.41
KCNQ2 O43526 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
P4HTM Q9NXG6 1/20 0.40
PIK3CA P42336 1/20 0.40
MTOR P42345 1/20 0.40
MALT1 Q9UDY8 1/20 0.40
ENPP1 P22413 1/20 0.39
HTT P42858 1/20 0.39
STAT3 P40763 1/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31554574 0.82 KCNQ3 (0.42) GRM4LMNAKCNQ3KCNQ2SMN1; SMN2
SCHEMBL19960767 0.81 ATR (0.46) ALDH1A1LMNAKCNQ3KCNQ2KDM4E
SCHEMBL3936252 0.78 PGK1 (0.43) GRM4ALDH1A1LMNAHDAC6KCNQ3
SCHEMBL6386383 0.78 MAOB (0.49) ALDH1A1LMNAKCNQ3KCNQ2SMN1; SMN2
SCHEMBL19814441 0.77 RORC (0.51) SMN1; SMN2RAB9APIK3CAMALT1
SCHEMBL19814401 0.76 MALT1 (0.50) GRM4SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL978676 0.75 CA12 (0.52) LMNARAB9AHTTMAPK1
SCHEMBL17512555 0.75 KCNQ3 (0.42) ALDH1A1KCNQ3KCNQ2SMN1; SMN2NPC1
SCHEMBL28941013 0.73 MEN1 (0.40) ALDH1A1HDAC6KDM4ENPC1RAB9A
SCHEMBL978445 0.73 MAPT (0.46) ALDH1A1KDM4EMEN1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 EP disclosed
EP-3510032-B1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORP (US) 2022-07-06 EP disclosed
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-09 US disclosed
US-10934288-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2021-03-02 US disclosed
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-19 US disclosed
US-10435405-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-10-08 US disclosed
EP-3510032-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER Incyte Corporation (US) 2019-07-17 EP disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
WO-2018049200-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 GRM4 3948/4885ALDH1A1 2205/4885LMNA 2520/4885
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 GRM4 3948/4885ALDH1A1 2205/4885LMNA 2520/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 GRM4 3948/4885ALDH1A1 2205/4885LMNA 2520/4885
US-10934288-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 GRM4 3948/4885ALDH1A1 2205/4885LMNA 2520/4885
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 GRM4 3948/4885ALDH1A1 2205/4885LMNA 2520/4885
US-10435405-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 GRM4 3948/4885ALDH1A1 2205/4885LMNA 2520/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 GRM4 3948/4885ALDH1A1 2205/4885LMNA 2520/4885
US-10266530-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 GRM4 3948/4885ALDH1A1 2205/4885LMNA 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.